Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

307
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
307
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

336
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
336
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

364
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
364
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

379
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
379
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

349
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
349
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

634
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
634

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine.

NPJ vaccines·2026
Same author

Subcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations.

mAbs·2026
Same author

Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations.

Antiviral research·2026
Same author

Multi-omics identification of quantitative trait loci associated with vascular pathogenesis and diagnostic potential in chronic venous disease.

Vascular pharmacology·2025
Same author

Low birth weight and chronic kidney disease with progression to kidney failure in children.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Medical Students' Attitudes Toward the COVID-19 Vaccine and Medical School Vaccine Education: A Survey Study.

Cureus·2025

Related Experiment Video

Updated: Mar 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Statistical Approaches to Assess Biosimilarity from Analytical Data.

Richard Burdick1, Todd Coffey2, Hiten Gutka3

  • 1Elion Labs, 1450 Infinite Drive, Louisville, Colorado, 80027, USA.

The AAPS Journal
|October 7, 2016
PubMed
Summary
This summary is machine-generated.

Analytical methods assess critical quality attributes (CQAs) for protein therapeutics, ensuring biosimilarity. Statistical rigor is applied to high-risk CQAs to confirm product similarity and safety for regulatory approval.

Keywords:
analytical methodscomparability and AAPS commentaryprotein therapeuticssimilarity

More Related Videos

A New Approach for the Comparative Analysis of Multiprotein Complexes Based on 15N Metabolic Labeling and Quantitative Mass Spectrometry
08:04

A New Approach for the Comparative Analysis of Multiprotein Complexes Based on 15N Metabolic Labeling and Quantitative Mass Spectrometry

Published on: March 13, 2014

12.7K
Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
07:34

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

13.5K

Related Experiment Videos

Last Updated: Mar 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
A New Approach for the Comparative Analysis of Multiprotein Complexes Based on 15N Metabolic Labeling and Quantitative Mass Spectrometry
08:04

A New Approach for the Comparative Analysis of Multiprotein Complexes Based on 15N Metabolic Labeling and Quantitative Mass Spectrometry

Published on: March 13, 2014

12.7K
Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
07:34

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

13.5K

Area of Science:

  • Biopharmaceutical analysis
  • Analytical chemistry
  • Regulatory science

Background:

  • Protein therapeutics possess unique critical quality attributes (CQAs) essential for purity, potency, and safety.
  • Analytical methods must discern clinically significant differences between comparator products.
  • Prioritizing CQAs by risk level (high, moderate, low) guides the application of statistical rigor.

Purpose of the Study:

  • To demonstrate the application of statistical approaches for analytical similarity assessments of protein therapeutics.
  • To provide a case study illustrating the evaluation of critical quality attributes (CQAs).
  • To highlight the importance of statistical rigor in establishing biosimilarity.

Main Methods:

  • Utilizing a case study approach to exemplify analytical similarity exercises.
  • Applying statistical equivalence testing for high-risk CQA measurements.
  • Evaluating qualitative high-risk CQAs (e.g., primary sequence) separately from quantitative attributes.

Main Results:

  • Demonstrated the use of statistical methods to establish similarity for high-risk CQAs.
  • Illustrated that some high-risk CQAs are qualitative and not suitable for equivalence testing.
  • Emphasized the need for sufficient originator drug product lots for robust statistical power.

Conclusions:

  • Analytical similarity evaluations, combined with PK/PD and immunogenicity data, support biosimilarity designations.
  • Appropriate statistical methods are crucial for demonstrating the similarity of protein therapeutics.
  • The totality of evidence, including analytical data, is necessary for regulatory approval of biosimilars.